Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sana Treatment in Fibromyalgia
NCT05394610Withdrawn
- Sponsor
- Sana Biotechnology
- Start
- Dec 2025
- Primary completion
- Dec 2026
01
Overview
Randomised, double-blind trial in fibromyalgia (FM) (2 arms), sponsored by Sana Biotechnology. Primary endpoint: Change in Fibromyalgia Symptoms at 6 weeks. Planned start Dec 2025; status: withdrawn.
02
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT05394610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394610.